Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death

Antimicrobial Agents and Chemotherapy
M KendeP G Canonico

Abstract

The prophylactic efficacy of poly(ICLC) (stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid) against Rift Valley fever virus infection in Swiss-Webster mice was dependent on the treatment schedule. The treatment schedule was optimized by ranking the results of various treatments by the Cox proportional-hazard model based on the incremental relative risk of death. With this ranking procedure, the schedule of choice was three doses of 20 micrograms each given 5 days apart. This regimen yielded a 90% survival rate. Additional parameters were determined, including the timing of the first and second drug dose, the temporal relationship of these treatments to the day of challenge, and the minimal effective dose (1 microgram per mouse).

Citations

Mar 28, 2009·International Journal of Molecular Sciences·Mary E Christopher, Jonathan P Wong
Jul 20, 1999·International Journal of Immunopharmacology·R L MillerM A Tomai
Jun 16, 1992·Annals of the New York Academy of Sciences·M Kende

Related Concepts

Poly ICLC, sodium salt
Metazoa
Ruspol
Drug Administration Schedule
Females
Subcutaneous Injections
Interferon Inducers
Cologel
Poly I-C
Poly-(Alpha-L-Lysine)

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.